Shares of Novo Nordisk nosedived as much as 10% after the drugmaker said a late-stage heart drug trial failed to reduce major cardiovascular events compared to a placebo.
While the experimental medicine, ziltivekimab, did show some biological effect, it didn’t translate into a statistically meaningful reduction in so-called MACE, defined as cardiovascular death, non-fatal heart attack or non-fatal stroke, for patients with certain diseases, Novo said in a statement on Friday.
“While ziltivekimab did not achieve the MACE benefit we had hoped for, this does not change our strategic commitment to cardiovascular disease,” chief scientific officer Martin Holst Lange said.
Copenhagen-listed shares were last seen down 8.6% while its American depositary receipts were 9.8% lower in premarket trading.
This is breaking news. Please refresh for updates.
